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ABSTRACT
Objective:  To date, no study has investigated the 
incidence of oral Kaposi’s sarcoma (OKS) in 
African populations affected by the human 
immunodeficiency virus (HIV) and the Acquired 
ImmunoDeficiency Syndrome AIDS epidemic. It is, 
therefore, the purpose of this study to assess the 
burden of OKS in the Zimbabwean population over 
a ten-year period.
Design:  A descriptive epidemiological study was 
undertaken to assess the burden of  OKS by 
determining the frequencies, incidence and 
cumulative rates, the lifetime risk  and odds of 
developing OKS according to site (topography), 
gender, age, race/ethnic  origin of the Zimbabwean 
population. Incident cases of OKS from the upper 
and lower lips, oral vestibule, retromolar area, floor 
of mouth, tongue, cheek mucosa, gums, hard and 
soft palate were accessed from the Zimbabwe 
National Cancer Registry (ZNCR). 
Cases from the skin, pharynx, larynx and the major 
salivary glands were excluded from the study.   
Setting:  This comprised the population of 
Zimbabwe during a ten-year period 1988 to 1997 
using population figures from the 1992 Census 
Zimbabwe National Report. The study population 
was standardised by the direct method against the 
world standard population to calculate the age 
standardized incidence rate (ASIR). The SPSS 
statistical software program (SPSS Inc.2001, USA) 
was used for the statistical analysis.
Results:  OKS comprised 0.92% of total body 
malignancies and 51% of oral malignancies with a 
mean age of study cases of 37.6 years and median 
age of 32 years. Histology of the primary (64.5%) 
and clinical diagnosis (34.6%) were the 
predominant methods of diagnosis. OKS affected 
almost exclusively blacks and males more than 
females with a male to female ratio of 1.9:1. The 
most affected age groups by OKS were the 30-34 for 
males and 25-29 for both females and the whole 
population. OKS 
mostly affected the palate (70,2%) followed by, in 
descending order, the tongue (13.3%) and mouth 
(8.3%). The age adjusted age standardised 
incidence rate (ASIR) of OKS exponentially 
increased the entire study period surpassing oral 
squamous cell carcinoma (OSCC) as the 
predominant oral malignancy in 1994. 
Conclusions:  OKS was the commonest 
malignancy of young adults affecting males more 
than females and surpassed oral squamous cell 
carcinoma in 1994 to become the commonest oral 
malignancy for the remainder of the study period. 
The palate was the most affected intraoral site by 
OKS. The possibility of human herpes virus 8 being 
HIV strain-specific in the aetiopathogenesis of oral 
Kaposi’s sarcoma warrants further investigation.  
Keywords: Oral Kaposi’s Sarcoma, palate, incidence rate, 
lifetime risk, human herpes virus 8.
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INTRODUCTION
Studies from Uganda, Rwanda, Zambia and 
Zimbabwe have reported sharp increases in the 
1-6
incidence of Kaposi’s sarcoma (KS)  which has 
become the most common malignancy associated 
with human immunodeficiency virus (HIV) 
infection and the acquired immunodeficiency 
1,2,7,8
syndrome (AIDS) epidemic . Oral Kaposi’s 
sarcoma (OKS) is one of the seven cardinal lesions 
strongly associated with HIV infection and 
indicates HIV infection. OKS presents as one of the 
early clinical features and is a marker of HIV disease 
12progression into full-blown AIDS as well as being a 
prognostic marker during Highly Active 
AntiRetroviral Treatment (HAART). Sub-Saharan 
Africa has the highest number of HIV/AIDS cases 
globally which contrasts with the lack of 
population-based studies on OKS; one of the 
clinical cardinal signs of HIV/AIDS. To date, no 
study has investigated the incidence of oral KS 
(OKS) in African populations affected by the 
HIV/AIDS epidemic. It is, therefore, the purpose of 
this study to assess the burden of OKS in the 
Zimbabwean population over a ten-year period.
METHODS
The burden of oral Kaposi’s sarcoma in Zimbabwe 
was assessed by determining the frequencies, 
incidence and cumulative rates, the lifetime risk and 
odds of developing OKS according to site 
(topography), gender, age and race/ethnic origin. 
During the study period, 1 January 1988 to 31 
December 1997, 445 cases of incident OKS out of a 
total of 873 oral malignancies and 47 906 cases of 
whole body malignancies were recorded by the 
Zimbabwe National Cancer Registry (ZNCR). The 
intraoral sites investigated include upper and lower 
lips, oral vestibule, retromolar area, floor of mouth, 
tongue, cheek mucosa, gums, hard and soft palate. 
Cases from the skin, pharynx, larynx and the major 
salivary glands were excluded from the study. 
Distinction between lip vermilion and lip mucosal 
malignancies was not clarified in the original ZNCR 
data; hence the inclusion of some lip vermilion KS 
among intraoral KS was a distinct possibility. Oral 
squamous cell carcinoma (OSCC) is a common oral 
malignancy that was used to assess the relative rate 
of increase of OKS. The accessed data for each case 
comprised information on age, gender, race, date of 
diagnosis, basis of diagnosis and site/topography. 
Absolute anonymity of identities of patients whose 
case details comprised the raw data for this study 
was maintained throughout the study. 
Population
The population figures used for this study were from 
the 1992 Census Zimbabwe National Report. 
Zimbabwe had a total population of 10 412 548 




The data was sorted into tables for males, females 
and the whole population in 5-year age groups 
against the site. The 5-year age groups and the upper 
limit of 75+ were set for concordance with the 1992 
Census population figures. Statistical analysis was 
done using the SPSS statistical software program 
(SPSS Inc.2001, USA). The age specific incidence 
rate, crude rate, age standardised incidence rate 
(ASIR), cumulative rate, the cumulative (lifetime) 
risk and odds of developing OKS were calculated 
using Microsoft Excel on Windows 98. The ASIR 
was age adjusted and standardised by the direct 
method against the world standard population. The 
cumulative rate was calculated using a defined life 
span of 0-74 years. It follows, therefore, that the 
chances of developing OKS that were calculated 
apply to the same life span of 0-74 years. 
RESULTS
OKS comprised 51% of oral malignancies and 
0.92% of total body malignancies recorded during 
the study period. The mean age of recorded patients 
was 37.6 years while the median age was 32 years. 
The racial distribution was almost exclusively 
blacks with only one case recorded in a 25-year old 
European female. Males bore the greater burden of 
OKS with 65.6% of recorded cases and a male: 
female ratio of 1.9:1. The majority of cases were 
diagnosed from the histology of the primary 
(64.5%) followed by clinical only (34.6%) while 
clinical, x-ray and ultra sound accounted for only 
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0.6%. Only one case of metastatic KS (0.2%) was 
recorded in the oral cavity. OKS mostly affected the 
palate (70.2%) followed by, in descending order, the 
tongue (13.3%) and mouth (8.3%). Frequencies for 
the other oral sites are as shown in Table I. 
Table I: Site/topographical distribution of oral Kaposi’s 
sarcoma
The most affected 5-year age groups by OKS were 
the 30-34 for males and 25-29 for both females and 
the whole population. Other notable peaks in OKS 
rates were in the 0-4 and the 75+ age groups. The 
ASIR of OKS increased steadily in all three 
population categories. A graphical plot of the ASIRs 
of OKS and OSCC by year of study in Figure 1 
shows OKS steadily increasing for the entire study 
period overtaking SCC in 1994. Interestingly, the 
ASIR of OSCC did not increase but stayed within a 
narrow range of 0.6 to 1.0 per 100000 personyears 
for eight of the ten years of study. 
The crude rate, age adjusted ASIR, cumulative rate, 
the lifetime risk and the chances to develop OKS of 
the study population are as given in Table II.
Table II: Rates, risks and odds of developing oral 
Kaposi’s sarcoma among males, females and the whole 
population
The corresponding figures for OSCC were 0.32 
/100000 personyears, 0.64 /100000 personyears, 
0.08%, and 0.01% with one chance in 1331 of 
developing OSCC for the study population. Males 
had higher ASIR for OKS (7.87 per 100 000 
personyears) and OSCC (9.18 per 100 000 
personyears) than females with 3.56 and 3.69 per 
100 000 personyears respectively. Males had the 
highest ASIR for OSCC a decade earlier (50-54 
five-year age group) than females (60-64 five-year 
age group) as depicted in figures 2 and 3. 
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Soft palate 6 1.3
Palate NOS 312 70.2
Cheek mucosa 3 0.7
Mouth NOS 37 8.3
Total 445 100.0
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Cumulative rate (%) 0.76 0.33 0.53
Cumulative (lifetime) risk  (%) 0.8 0.3 0.5
Odds of developing OKS 1:132 1:299 1:188
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Among AIDS-associated malignancies, OKS 
accounted for 98% while the balance comprised 
Burkitt’s lymphoma, Hodgkin’s and Non-Hodgkin’s 
lymphomas, haemangiosarcoma and lymphoma not 
otherwise specified. 
DISCUSSION
This study was prompted by a previous population-
based study of the burden of oral malignancies in 
Zimbabwe where OKS was the commonest oral 
14
malignancy and mostly affected the palate . 
7,13
Previous studies from Zimbabwe  on general 
cancer trends have reported dramatic increases in the 
incidence of Kaposi’s sarcoma (KS) making KS the 
most common cancer in males and the second most 
common in females after cervical cancer. In this 
study, the study population is seven times more 
likely to develop OKS than OSCC while males have 
double the chances of developing OKS compared to 
females. Consequently Kaposi’s sarcoma has 
overtaken squamous cell carcinoma to become the 
most common form of oral malignancy in the three 
population categories of males, females and the 
whole population during the study period. These 
changes were due to the HIV/AIDS epidemic in 
Zimbabwe where some of the highest HIV infection 
15
rates have been reported  and non-provision of 
Highly Active AntiRetroviral Treatment (HAART) 
in the public health sector during the study period. 
The frequency of other AIDS associated 
malignancies in this study is very low. This can be 
attributed to a number of reasons. Despite the 
Zimbabwe National Cancer Registry attaining 
international accreditation for quality of its data 
during the study period by the International Agency 
for Research on Cancer (Lyon, France), missed cases 
remain an inherent weakness of studies using 
registry data. Another explanation could have been 
occurrence of the bulk of such malignancies at 
extraoral sites or death of the patients before 
intraoral involvement. It has been reported that 
survival of cases with AIDS related KS is worse in 
younger than in older age groups and the median 
survival for AIDS patients presenting with KS is 
16
between 19 and 22 months . The non-provision of 
HAART during the study period at state hospitals in 
Zimbabwe worsened the prognosis of patients with 
KS. 
The role of the g herpesvirus, human herpes virus 8 
(HHV-8), in the pathogenesis of KS presents 
conflicting views. There is a widely held view that 
HHV-8 plays a synergistic role in the pathogenesis 
16-20
of KS . HIV-1 is the most prevalent HIV strain in 
14Zimbabwe . However, evidence from Ivory Coast 
in West Africa prompts a revision of this view. A 
study from Ivory Coast reported high anti-HHV-8 
antibodies comparable to levels seen in the high KS 
incidence areas and also that KS was a much less 
frequent complication of HIV-2 infection than it was 
22of HIV-1 infection . The same authors also reported 
that increases in infection rates since 1987 had been 
largely due to the transmission of HIV-1, whereas 
the infection rates of HIV-2 had remained stable or 
had declined.  Furthermore, the same group of 
authors found that prior to the AIDS epidemic, KS 
was a relatively rare cancer in West Africa compared 
with the endemic areas in east and southern Africa. 
In their opinion, this did not appear to reflect a 
marked difference in the prevalence of infection 
with the causative agent, human herpes virus 8 
(HHV8), because seroprevalence of anti-HHV-8 
antibodies in West Africa was high and quite 
comparable to that seen in the high incidence areas 
for KS. In view of these findings, it can be 
hypothesised that in sub-Saharan Africa, HHV-8 
plays a HIV strain selective synergistic role in the 
pathogenesis of KS. This role is illustrated with the 
HIV-1 strain and not HIV-2 strain. The high HHV-8 
infection levels already prevalent in West Africa are 
fertile ground for the HIV-1 strain and dramatic 
increases in the incidence of KS more specifically 
OKS can be anticipated. This point calls for further 
studies from West Africa where HIV-1 infection has 
been on the increase and strengthening of oral health 
screening programs. 
Oral KS by age.
The high rates of OKS in the 0-4 age group suggest 
that a high proportion of babies were born HIV 
positive then developed OKS in infancy as observed 
14in a Zimbabwean study of total body KS . At the 
other end of the age spectrum, the 75+ age group 
also had high OKS rates. The latter increase most 
likely reflects rates of the endemic form, which 
usually affects the lower extremities of the elderly 
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than the epidemic form of KS or a mixture of the 
two. However, at which age group the epidemic 
form ends and the endemic form starts remains 
imprecise. This is further complicated by the 
reported increase of classic KS in Greece and a 
23
speculative role of HHV-8 in this increase . This 
study illustrates that OKS is predominantly a 
disease of young adults, which is attributable to the 
HIV/AIDS epidemic.
Oral KS by site
The oral KS frequency of 51% in this study 
represents a ten-fold increase of KS frequencies 
5
reported in an earlier study in Zimbabwe . Though 
the palate is the most commonly affected intraoral 
24
site in this study and Uganda  there are differences 
in subsequent intraoral sites affected by OKS as the 
Ugandan study had the palate followed by the 
gingiva, tongue and tonsil. Ziegler and Katongole-
Mbidde (1996) reported a similar intraoral site 
distribution of OKS in another study from the same 
25
geographical region of east Africa . Canto and 
Devesa (2002) reported that OKS accounted for 
1.2%, mainly occurring on the hard palate and only 
2610% of total KS cases were found in the pharynx . 
It can be concluded that even though the palate is 
the most commonly affected intraoral site, 
differences do occur at other intraoral sites affected 
by OKS possibly due to geographical and or 
intrinsic factors. 
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